These references are extracted from the WHO Position Paper to have an overview of the sources that were used in the Position Paper.
World Health Organization. (2019). Typhoid vaccines: WHO position paper, March 2018–Recommendations. Vaccine, 37(2), 214-216.
Sirima, S. B., Ouedraogo, A., Barry, N., Siribie, M., Tiono, A., Nébié, I., ... & Laurens, M. B. (2021). Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: a randomized controlled phase 2 trial. International Journal of Infectious Diseases, 108, 465-472. https://doi.org/10.1016/j.ijid.2021.05.061
Thompson CN et al. Typhoid fever in Fiji: a reversible plague? Trop Med Int Health. 2014;19:1284–1292. https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/tmi.12367
Als, D., Radhakrishnan, A., Arora, P., Gaffey, M. F., Campisi, S., Velummailum, R., ... & Bhutta, Z. A. (2018). Global trends in typhoidal salmonellosis: a systematic review. American Journal of Tropical Medicine and Hygiene, 99(Suppl 3), 10. https://ecommons.aku.edu/cgi/viewcontent.cgi?article=1651&context=pakistan_fhs_mc_women_childhealth_paediatr
Baker, S., Holt, K. E., Clements, A. C., Karkey, A., Arjyal, A., Boni, M. F., ... & Farrar, J. J. (2011). Combined high-resolution genotyping and geospatial analysis reveals modes of endemic urban typhoid fever transmission. Open biology, 1(2), 110008. https://iris.who.int/bitstream/handle/10665/272272/WER9313.pdf?sequence=1
Marks, F., von Kalckreuth, V., Aaby, P., Adu-Sarkodie, Y., El Tayeb, M. A., Ali, M., ... & Wierzba, T. F. (2017). Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. The Lancet Global Health, 5(3), e310-e323. https://www.thelancet.com/action/showPdf?pii=S2214-109X%2817%2930022-0
Azmatullah, A., Qamar, F. N., Thaver, D., Zaidi, A. K., & Bhutta, Z. A. (2015). Systematic review of the global epidemiology, clinical and laboratory profile of enteric fever. Journal of global health, 5(2). https://www.jogh.org/documents/issue201502/jogh-05-020407.pdf
Breiman, R. F., Cosmas, L., Njuguna, H., Audi, A., Olack, B., Ochieng, J. B., ... & Feikin, D. R. (2012). Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in Africa. PloS one, 7(1), e29119. https://doi.org/10.1371/journal.pone.0029119
Feasey, N. A., Gaskell, K., Wong, V., Msefula, C., Selemani, G., Kumwenda, S., ... & Heyderman, R. S. (2015). Rapid emergence of multidrug resistant, H58-lineage Salmonella typhi in Blantyre, Malawi. PLoS neglected tropical diseases, 9(4), e0003748. https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0003748&type=printable
Britto, C., Pollard, A. J., Voysey, M., & Blohmke, C. J. (2017). An appraisal of the clinical features of pediatric enteric fever: systematic review and meta-analysis of the age-stratified disease occurrence. Clinical Infectious Diseases, 64(11), 1604-1611. https://doi.org/10.1093/cid/cix229
Carles, G., Montoya, Y., Seve, B., Rakotofananina, T., Largeaud, M., & Mignot, V. (2002). Typhoid fever and pregnancy. Journal de gynecologie, obstetrique et biologie de la reproduction, 31(5), 495-499.
Sulaiman, K., & Sarwari, A. R. (2007). Culture-confirmed typhoid fever and pregnancy. International Journal of Infectious Diseases, 11(4), 337-341 https://doi.org/10.1016/j.ijid.2006.09.007
Watson, C. H., Baker, S., Lau, C. L., Rawalai, K., Taufa, M., Coriakula, J., ... & Edmunds, W. J. (2017). A cross-sectional seroepidemiological survey of typhoid fever in Fiji. PLoS neglected tropical diseases, 11(7), e0005786. https://doi.org/10.1371/journal.pntd.0005786
Levine, M. M. (2018). Typhoid fever vaccines. In Plotkin's Vaccines (pp. 1114-1144). Elsevier.
Muyembe-Tamfum, J. J., Veyi, J., Kaswa, M., Lunguya, O., Verhaegen, J., & Boelaert, M. (2009). An outbreak of peritonitis caused by multidrug-resistant Salmonella Typhi in Kinshasa, Democratic Republic of Congo. Travel medicine and infectious disease, 7(1), 40-43. (NOT OA)
Neil, K. P., Sodha, S. V., Lukwago, L., O-tipo, S., Mikoleit, M., Simington, S. D., ... & Mintz, E. (2012). A large outbreak of typhoid fever associated with a high rate of intestinal perforation in Kasese District, Uganda, 2008–2009. Clinical infectious diseases, 54(8), 1091-1099. https://doi.org/10.1093/cid/cis025
Bhutta, Z. A. (1996). Impact of age and drug resistance on mortality in typhoid fever. Archives of disease in childhood, 75(3), 214-217. https://pmc.ncbi.nlm.nih.gov/articles/PMC1511710/pdf/archdisch00609-0052.pdf
Gonzalez-Escobedo, G., Marshall, J. M., & Gunn, J. S. (2011). Chronic and acute infection of the gall bladder by Salmonella Typhi: understanding the carrier state. Nature Reviews Microbiology, 9(1), 9-14. doi: 10.1038/nrmicro2490
Koshiol, J., Wozniak, A., Cook, P., Adaniel, C., Acevedo, J., Azócar, L., ... & Hildesheim, A. (2016). Salmonella enterica serovar Typhi and gallbladder cancer: a case–control study and meta‐analysis. Cancer Medicine, 5(11), 3310-3235. https://doi.org/10.1002/cam4.915
Wijedoru, L., Mallett, S., & Parry, C. M. (2017). Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD008892.pub2
Gaind, R., Paglietti, B., Murgia, M., Dawar, R., Uzzau, S., Cappuccinelli, P., ... & Rubino, S. (2006). Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India. Journal of antimicrobial chemotherapy, 58(6), 1139-1144. (NOT OA)
Arjyal, A., Basnyat, B., Nhan, H. T., Koirala, S., Giri, A., Joshi, N., ... & Dolecek, C. (2016). Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial. The Lancet infectious diseases, 16(5), 535-545. https://www.thelancet.com/action/showPdf?pii=S1473-3099%2815%2900530-7
Keddy, K. H., Smith, A. M., Sooka, A., Ismail, H., & Oliver, S. (2010). Fluoroquinolone-resistant typhoid, South Africa. Emerging infectious diseases, 16(5), 879. doi: 10.3201/eid1605.091917
Lunguya, O., Lejon, V., Phoba, M. F., Bertrand, S., Vanhoof, R., Verhaegen, J., ... & Jacobs, J. (2012). Salmonella typhi in the democratic republic of the congo: fluoroquinolone decreased susceptibility on the rise. PLoS neglected tropical diseases, 6(11), e1921. https://doi.org/10.1371/journal.pntd.0001921
Crump, J. A., Sjölund-Karlsson, M., Gordon, M. A., & Parry, C. M. (2015). Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. Clinical microbiology reviews, 28(4), 901-937. DOI: https://doi.org/10.1128/cmr.00002-15
Yousafzai, M. T., Qamar, F. N., Shakoor, S., Saleem, K., Kazi, M., Garett, D., & Luby, S. (2017, April). Outbreak investigation of cefriaxone resistant S. Typhi in Hyderabad, Pakistan. In 10th International Conference on Typhoid & other Invasive Salmonellosis https://www.coalitionagainsttyphoid.org/wp-content/uploads/2016/07/16-Outbreak-Investigation-and-Assessment-of-Risk-Factors-of-Ceftriaxone-Resistant-S.-Typhi-from-Hyderabad-Pakistan.pdf
Wong, V. K., Baker, S., Connor, T. R., Pickard, D., Page, A. J., Dave, J., ... & Holt, K. E. (2016). An extended genotyping framework for Salmonella enterica serovar Typhi, the cause of human typhoid. Nature communications, 7(1), 12827.
Wong, V. K., Baker, S., Pickard, D. J., Parkhill, J., Page, A. J., Feasey, N. A., ... & Dougan, G. (2015). Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter-and intracontinental transmission events. Nature genetics, 47(6), 632-639. https://www.nature.com/articles/ng.3281.pdf
Kariuki, S., Revathi, G., Kiiru, J., Mengo, D. M., Mwituria, J., Muyodi, J., ... & Dougan, G. (2010). Typhoid in Kenya is associated with a dominant multidrug-resistant Salmonella enterica serovar Typhi haplotype that is also widespread in Southeast Asia. Journal of clinical microbiology, 48(6), 2171-2176. DOI: https://doi.org/10.1128/jcm.01983-09
International Typhoid Consortium, Wong, V. K., Holt, K. E., Okoro, C., Baker, S., Pickard, D. J., ... & Obaro, S. (2016). Molecular surveillance identifies multiple transmissions of typhoid in West Africa. PLoS neglected tropical diseases, 10(9), e0004781. https://doi.org/10.1371/journal.pntd.0004781
Parry, C. M., Thompson, C., Vinh, H., Chinh, N. T., Phuong, L. T., Ho, V. A., ... & Baker, S. (2014). Risk factors for the development of severe typhoid fever in Vietnam. BMC infectious diseases, 14, 1-9. https://link.springer.com/content/pdf/10.1186/1471-2334-14-73.pdf
Mermin, J. H., Villar, R., Carpenter, J., Roberts, L., Samaridden, A., Gasanova, L., ... & Mintz, E. D. (1999). A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water. The Journal of infectious diseases, 179(6), 1416-1422. (NOT OA)
WHO. Expert Committee on Biological Standardization. Sixty-fourth report. WHO technical report series; no. 987. 2013. Available at http://apps.who.int/iris/ bitstream/handle/.10665/129494/TRS_987_eng.pdf,
WHO. List of prequalified vaccines https://extranet.who.int/prequal/vaccines/list-prequalified-vaccines
Mohan, V. K., Varanasi, V., Singh, A., Pasetti, M. F., Levine, M. M., Venkatesan, R., & Ella, K. M. (2015). Safety and immunogenicity of a Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clinical Infectious Diseases, 61(3), 393-402. https://doi.org/10.1093/cid/civ295
Jin, C., Gibani, M. M., Moore, M., Juel, H. B., Jones, E., Meiring, J., ... & Pollard, A. J. (2017). Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. The Lancet, 390(10111), 2472-2480. https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)32149-9.pdf
Lanh, M.N., Van Bay, P., Ho, V.A., Thanh, T.C., Lin, F.Y.C., Bryla, D.A., Chu, C., Schiloach, J., Robbins, J.B., Schneerson, R. and Szu, S.C., 2003. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. New England Journal of Medicine, 349(14), pp.1390-1391. (NOT OA)
Voysey, M., & Pollard, A. J. (2018). Seroefficacy of Vi polysaccharide–tetanus toxoid typhoid conjugate vaccine (Typbar TCV). Clinical Infectious Diseases, 67(1), 18-24.https://doi.org/10.1093/cid/cix1145
Darton, T. C., Jones, C., Blohmke, C. J., Waddington, C. S., Zhou, L., Peters, A., ... & Pollard, A. J. (2016). Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a. PLoS neglected tropical diseases, 10(8), e0004926. https://doi.org/10.1371/journal.pntd.0004926
Acharya, I. L., Lowe, C. U., Thapa, R., Gurubacharya, V. L., Shrestha, M. B., Cadoz, M., ... & Robbins, J. B. (1987). Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. New England Journal of Medicine, 317(18), 1101-1104. (NOT OA)
Klugman, K., Koornhof, H., Schneerson, R., Cadoz, M., Gilbertson, I., Robbins, J., ... & COMMITTEE, V. A. (1987). Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. The Lancet, 330(8569), 1165-1169. (NOT OA)
Plotkin, S. A., & Bouveret-Le Cam, N. (1995). A new typhoid vaccine composed of the Vi capsular polysaccharide. Archives of internal medicine, 155(21), 2293-2299.(NOT OA)
Froeschle, J. E., & Decker, M. D. (2010). Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever. Vaccine, 28(6), 1451-1453. (NOT OA)
Overbosch, D., Peyron, F., Picot, N., Varichon, J. P., Dumas, R., Chambonneau, L., & Weber, F. (2005). Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years. Journal of travel medicine, 12(6), 319-326. (NOT OA)
Keitel, W. A., Bond, N. L., Zahradnik, J. M., Cramton, T. A., & Robbins, J. B. (1994). Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine, 12(3), 195-199. (NOT OA)
Roggelin, L., Vinnemeier, C. D., Fischer-Herr, J., Johnson-Weaver, B. T., Rolling, T., Burchard, G. D., ... & Cramer, J. P. (2015). Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers. Vaccine, 33(33), 4141-4145. (NOT OA)
Zhou, W. Z., Koo, H. W., Wang, X. Y., Zhang, J., Park, J. K., Zhu, F., ... & Clemens, J. D. (2007). Revaccination with locally-produced vi typhoid polysaccharide vaccine among Chinese school-aged children: safety and immunogenicity findings. The Pediatric infectious disease journal, 26(11), 1001-1005. (NOT OA)
Yang, H. H., Wu, C. G., Xie, G. Z., Gu, Q. W., Wang, B. R., Wang, L. Y., ... & Li, G. L. (2001). Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bulletin of the World Health Organization, 79, 625-631. https://www.scielosp.org/article/ssm/content/raw/?resource_ssm_path=/media/assets/bwho/v79n7/v79n7a07.pdf
Sur, D., Ochiai, R. L., Bhattacharya, S. K., Ganguly, N. K., Ali, M., Manna, B., ... & Clemens, J. D. (2009). A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. New England Journal of Medicine, 361(4), 335-344. (NOT OA)
Khan, M. I., Soofi, S. B., Ochiai, R. L., Habib, M. A., Sahito, S. M., Nizami, S. Q., ... & DOMI Typhoid Karachi Vi Effectiveness Study Group. (2012). Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine, 30(36), 5389-5395. (NOT OA)
Michel, R., Garnotel, E., Spiegel, A., Morillon, M., Saliou, P., & Boutin, J. P. (2005). Outbreak of typhoid fever in vaccinated members of the French Armed Forcesin the Ivory Coast. European journal of epidemiology, 20, 635-642. (NOT OA)
Salerno-Goncalves, R., Pasetti, M. F., & Sztein, M. B. (2002). Characterization of CD8+ effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. The Journal of Immunology, 169(4), 2196-2203. https://doi.org/10.4049/jimmunol.169.4.2196
Wahid, R., Fresnay, S., Levine, M. M., & Sztein, M. B. (2015). Immunization with Ty21a live oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A, and S. Paratyphi B in humans. Mucosal immunology, 8(6), 1349-1359. (NOT OA)
Levine, M. M., Ferreccio, C., Black, R. E., Tacket, C. O., Germanier, R., & Chilean Typhoid Committee. (1989). Progress in vaccines against typhoid fever. Clinical Infectious Diseases, 11(Supplement_3), S552-S567. (NOT OA)
Kantele, A. (1990). Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine, 8(4), 321-326. (NOT OA)
Gilman, R. H., Hornick, R. B., Woodward, W. E., DuPont, H. L., Snyder, M. J., Levine, M. M., & Libonati, J. P. (1977). Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a live oral vaccine. Journal of infectious diseases, 136(6), 717-723. (NOT OA)
Wahdan, M. H., Serie, C. H., Cerisier, Y., Sallam, S., & Germanier, R. (1982). A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. Journal of Infectious Diseases, 145(3), 292-295. (NOT OA)
Levine, M., Black, R., Ferreccio, C., Germanier, R., & Committee, C. T. (1987). Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. The Lancet, 329(8541), 1049-1052. (NOT OA)
Levine, M. M., Ferreccio, C., Abrego, P., San Martin, O., Ortiz, E., & Cryz, S. (1999). Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine, 17, S22-S27. (NOT OA)
Levine, M. M., Ferreccio, C., Black, R. E., Lagos, R., Martin, O. S., & Blackwelder, W. C. (2007). Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical infectious diseases, 45(Supplement_1), S24-S28.(NOT OA)
Simanjuntak, C. H., Totosudirjo, H., Haryanto, P., Suprijanto, E., Paleologo, F. P., Punjabi, N. H., ... & Hoffman, S. L. (1991). Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. The Lancet, 338(8774), 1055-1059. (NOT OA)
Klugman, K. P., Koornhof, H. J., Robbins, J. B., & Le Cam, N. N. (1996). Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine, 14(5), 435-438. (NOT OA)
Keddy, K. H., Klugman, K. P., Hansford, C. F., Blondeau, C., & le Cam, N. N. B. (1999). Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization. Vaccine, 17(2), 110-113. (NOT OA)
Ochiai, R. L., Acosta, C. J., Agtini, M., Bhattacharya, S. K., Bhutta, Z. A., Do, C. G., ... & Clemens, J. D. (2007). The use of typhoid vaccines in Asia: the DOMI experience. Clinical infectious diseases, 45(Supplement_1), S34-S38. (NOT OA)
Kroon, F. P., van Dissel, J. T., Ravensbergen, E., Nibbering, P. H., & van Furth, R. (1999). Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi®). Vaccine, 17(23-24), 2941-2945. (NOT OA)
UNAIDS. GLOBAL AIDS UPDATE. 2017.https://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update_2017_en.pdf
Antillón, M., Bilcke, J., Paltiel, A. D., & Pitzer, V. E. (2017). Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low-and middle-income settings. Vaccine, 35(27), 3506-3514.https://doi.org/10.1016/j.vaccine.2017.05.001
Lo, N. C., Gupta, R., Stanaway, J. D., Garrett, D. O., Bogoch, I. I., Luby, S. P., & Andrews, J. R. (2018). Comparison of strategies and incidence thresholds for Vi conjugate vaccines against typhoid fever: a cost-effectiveness modeling study. The Journal of infectious diseases, 218(suppl_4), S232-S242. https://doi.org/10.1093/infdis/jix598
Cook, J., Jeuland, M., Whittington, D., Poulos, C., Clemens, J., Sur, D., ... & DOMI Typhoid Economics Study Group. (2008). The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine, 26(50), 6305-6316. (NOT OA)
Carias, C., Walters, M. S., Wefula, E., Date, K. A., Swerdlow, D. L., Vijayaraghavan, M., & Mintz, E. (2015). Economic evaluation of typhoid vaccination in a prolonged typhoid outbreak setting: the case of Kasese district in Uganda. Vaccine, 33(17), 2079-2085. (NOT OA)
WHO. Evidence to Recommendation Table: Typhoid Vaccines. https://cdn.who.int/media/docs/default-source/immunization/position_paper_documents/typhoid/6-sage-typhoid-e2r-final.pdf?sfvrsn=fcaa83ec_2